New hope for prostate cancer recurrence: targeted radiation plus radioactive drug combo tested
NCT ID NCT06105918
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether combining two types of targeted radiation is safe for men whose prostate cancer has returned after prostate removal surgery. The treatment uses a special scan to find cancer cells, then delivers high-energy rays and a radioactive drug directly to those cells. Only 6 participants are enrolled to check for side effects and find the best dose.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIOCHEMICALLY RECURRENT PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can surgery boost control of spread prostate cancer?
- Can a better scan sharpen radiation for prostate cancer?
- Hormone therapy showdown: can an oral pill beat the shot for prostate cancer patients?
- Can tracking tumor movement during radiation make treatment more precise?
- Can a single small incision preserve sexual function after prostate cancer surgery?
- Can a shorter course of radiation tame prostate cancer with fewer side effects?